Colorectal cancer is the third leading cause of cancer-related deaths. Clinical responses of metastatic colorectal cancer to first-line treatment range from 35 to 60 percent, but even responders inevitably develop therapeutic resistance. Liquid biopsies have become a useful tool in precision medicine for therapy selection and have immense potential as a monitoring tool for the emergence of therapy resistance.
This poster from Canexia Health presents data from a study investigating if longitudinal plasma ctDNA mutation monitoring can aid in predicting clinical progression before standard-of-care CT imaging, with the goal of establishing the Follow It assay as a liquid biopsy tool to assess progression over time in metastatic colorectal cancer patients.
Offered Free by: Canexia Health
See All Resources from: Canexia Health